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800Objective: We sought to determine the clinical outcomes of patients undergoing surgical aortic valve replace-
ment with hemodynamically confirmed severe pulmonary hypertension and aortic stenosis and compare them
with the outcomes of patients not undergoing aortic valve replacement and patients undergoing aortic valve
replacement with mild-to-moderate pulmonary hypertension.
Methods: A total of 317 patients with severe aortic stenosis (aortic valve area<1 cm2) underwent right heart
catheterization along with left heart catheterization between 2004 and 2009. Severe pulmonary hypertension
(mean pulmonary artery pressure>35 mm Hg) was present in 81 patients, of whom 35 (43.2%) underwent sur-
gical aortic valve replacement. We compared the clinical outcomes of these 35 patients with the 46 patients with
severe pulmonary hypertension who did not undergo surgical aortic valve replacement.
Results: Thirty-day mortality after aortic valve replacement was 2.85% in patients with severe pulmonary hy-
pertension and 10.86% in patients not undergoing aortic valve replacement (P¼ .001). During amean follow-up
of 339.0 343.7 days, overall mortality in patients undergoing aortic valve replacement was 14.2% in patients
with severe pulmonary hypertension and 50% in patients with severe pulmonary hypertension who did not un-
dergo aortic valve replacement (P<.0001). On the other hand, among patients who underwent surgery, overall
mortality was similar in both the mild-to-moderate pulmonary hypertension group (23 patients [20.3%]) and the
severe pulmonary hypertension group at the end of the follow-up period (P¼ .4). In a multivariate analysis, the
presence of chronic obstructive pulmonary disease and the lack of reduction in mean pulmonary artery pressure
were independent predictors of mortality in these high-risk patients undergoing aortic valve replacement,
whereas baseline mean pulmonary artery pressure was not a predictor. Preoperative pulmonary capillary wedge
pressure was a significant predictor of postoperative reduction in mean pulmonary artery pressure.
Conclusions: In patients with severe aortic stenosis and severe pulmonary hypertension who undergo aortic
valve replacement, baseline pulmonary artery pressure does not unfavorably affect survival. Aortic valve re-
placement should be considered for patients with aortic stenosis with severe pulmonary hypertension, especially
with higher pulmonary capillary wedge pressure. (J Thorac Cardiovasc Surg 2011;142:800-8)The prevalence of pulmonary hypertension (PH) (28%–
56%) and severe PH (11%–21%) in the setting of severe
aortic stenosis (AS) varies depending on patient selection
criteria and the threshold of pulmonary artery pressure
(PAP) used for definition of PH.1-4 The cause of severe
PH in this clinical setting may be attributed to left
ventricular systolic or diastolic dysfunction.1-5 When
present, PH is a harbinger for potential sudden death and
clinical deterioration.6
Although aortic valve replacement (AVR) for severe AS
can be safely performed in most patients, surgical optionse Departments of Internal Medicine,a Cardiovascular Medicine,b and Tho-
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The Journal of Thoracic and Cardiovascular Surgmay be limited in the elderly and in subjects with multiple
comorbidities.7-10 A significant proportion of these high-
risk surgical candidates may now be optimally managed us-
ing transcatheter aortic valve implantation. The availability
of this less-invasive technique heightens the importance of
accurate surgical risk assessment by the referring clini-
cian.11 The ultimate decision to proceed with a conventional
surgical procedure is then based on assessing the benefit
that the individual patient is likely to derive over the inher-
ent risk of the planned procedure.
Although an earlier study reported preoperative PH im-
paired long-term prognosis of patients after AVR,12 more
recent studies have shown low operative mortality and
excellent symptomatic improvement in patients with severe
AS with severe PH after AVR,4,13 with a rapid improvement
in systolic and diastolic PAPs13-15 that has translated into
a favorable long-term clinical outcome.14,16 A significant
limitation of these prior analyses was their dependence on
echocardiography-derived estimation of systolic PAP using
the tricuspid valve regurgitation jet velocity. Tricuspid
valve regurgitation jet velocity can be detected in onlyery c October 2011
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVA ¼ aortic valve area
AVR ¼ aortic valve replacement
CI ¼ confidence interval
COPD ¼ chronic obstructive pulmonary disease
HR ¼ hazard ratio
LVEDP ¼ left ventricular end-diastolic pressure
NYHA ¼ New York Heart Association
OR ¼ odds ratio
PCWP ¼ pulmonary capillary wedge pressure
PH ¼ pulmonary hypertension
PAP ¼ pulmonary artery pressure
STS ¼ Society of Thoracic Surgeons
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have enough signals for pressure measurement.17 However,
right heart catheterization is the only method for direct mea-
surement of an increased pressure in pulmonary circulatory
system. Therefore, right heart catheterization has a higher
specificity and is the gold standard for the diagnosis of
PH.18,19 To date, only 3 catheter-based hemodynamic stud-
ies with small patient numbers have been published in this
population with limited survival data.1,4,13 Data on short-
and long-term mortality and predictors of mortality are
also lacking. Although postoperative reduction in PAP has
been shown after AVR,13-15 it is not clear which patients
will respond favorably and whether a favorable
hemodynamic response predicts better outcome in this
clinical subset. Accordingly, we reviewed our experience
to determine the prognostic effect of catheter-diagnosed se-
vere PH in patients with severe AS by using catheterization-
based hemodynamic data.MATERIALS AND METHODS
Study Population
We retrospectively reviewed patient records at the Cleveland Clinic
from January 2004 to April 2009 to determine patients with severe AS (aor-
tic valve area [AVA]<1 cm2) who underwent right and left heart catheter-
ization. Patients with clinically severe chronic obstructive pulmonary
disease (COPD) (a volume of air exhaled within the first second of forced
expiratory maneuver<50% of predicted value and forced expiratory vol-
ume in 1 second/forced vital capacity<0.7), primary PH frommedical his-
tory, interstitial lung disease (eg, diseases involving the parenchyma of the
lung, idiopathic pulmonary fibrosis, connective tissue disease, asbestosis,
sarcoidosis), concomitant severe mitral stenosis, or previous AVRwere ex-
cluded. We identified 317 patients with severe AS who had undergone both
left and right heart catheterization during the study period. Severe PH was
defined as mean PAP greater than 35 mm Hg.20 In our data set, 81 patients
had severe PH and 35 of them (43.2%) underwent surgical AVR. On the
other hand, 236 patients had mild-to-moderate PH (mean PAP  35 mm
Hg) and 114 of these patients underwent surgical AVR. We compared
the clinical outcomes of patients with severe PH who underwent surgicalThe Journal of Thoracic and CaAVR with those who did not undergo surgical AVR and with patients
with mild-to-moderate PH who underwent surgical AVR.
Baseline patient characteristics and clinical follow-up variables were
obtained from medical records after the Cleveland Clinic Institutional Re-
view Board approved our study. Age, gender, body mass index, symptoms
(angina, dyspnea, or syncope and presyncope), aortic valve morphology,
functional New York Heart Association (NYHA) class, creatinine level,
smoking history, hypertension, diabetes, COPD, myocardial infarction,
coronary artery bypass graft surgery, significant coronary artery disease
(stenosis>50%), and atrial fibrillation were noted as baseline characteris-
tics at the time of index heart catheterization. We also calculated predicted
Society of Thoracic Surgeons (STS) surgical risk scores of all patients
using the STS website (http://209.220.160.181/STSWebRiskCalc261/).
Date of surgery, concomitant surgeries, postoperative complications,
length of hospital stay, and postoperative NYHA class were recorded for
surgical outcomes. Postoperative death, repeated sternotomy, prolonged
ventilation (ventilation>48 hours), tracheostomy, atrial fibrillation, perma-
nent pacemaker, acute myocardial infarction, stroke, chronic renal insuffi-
ciency (>2 mg/dL creatinine or>1 mg/dL increase), dialysis, multiorgan
failure, and sepsis were considered as postoperative complications.
We searched the Social Security Death Index in May 2009 to determine
mortality. Date of surgery was the origin for survival analysis, and mortal-
ity outcomes included all deaths to May 2009. In patients who did not un-
dergo surgery, the date of index right heart catheterization was the zero
point for survival analysis. Death within 1 month after surgery or index
heart catheterization (for no AVR group) was defined as 30-day mortality.
Echocardiographic Methods
Echocardiographic data were obtained from the last available 2-dimen-
sional and Doppler transthoracic echocardiography before index heart
catheterization. Effective AVA using the continuity equation, left ventricu-
lar ejection fraction, mean and peak aortic transvalvular gradients using
continuous-wave Doppler across the left ventricular outflow tract, and pres-
ence of concurrent aortic valve insufficiency, mitral valve regurgitation,
mitral stenosis, and right ventricle systolic dysfunction were noted from
echocardiographic studies.
Hemodynamic Methods
Right and left cardiac catheterization and coronary angiography were
performed according to physician judgment for patients with severe AS.
AVA, peak gradient, mean gradient, systolic PAP, diastolic PAP, mean
PAP, mean pulmonary capillary wedge pressure (PCWP), cardiac output
and cardiac index (Fick method), and left ventricular end-diastolic pressure
(LVEDP) were obtained from cardiac catheterization laboratory records.
Pulmonary vascular resistance was calculated in units of dynes/sec/cm5
as 80 3 (mean PAP – mean PCWP)/cardiac output. We evaluated postop-
erative changes of systolic PAP, diastolic PAP, and mean PAP using Swan-
Ganz catheter-derived pressures in the postoperative intensive care unit.
The last reading before withdrawing the catheter was accepted for analysis.
The change in mean PAP after surgery was also assessed.
Statistical Analysis
Statistical analysis was performed using Stata v. 10.0 (StataCorp LP,
College Station, Tex) statistical software. Bivariate comparisons between
the mild-to-moderate and severe PH groups were drawn using the Student
t test and Kruskal–Wallis test for continuous and discrete data, respectively.
Unadjusted Kaplan–Meier survival analysis was used to compare long-
term mortality between the 2 groups. After verification of standard model-
ing assumptions, we used a Cox proportional hazardsmodeling approach to
determine significant predictors of mortality in our study population. On
the basis of reduction of mean PAP, the study population was divided
into 2 groups: responders (patients with  10 mm Hg decrease in mean
PAP after AVR) and nonresponders (patients with<10 mm Hg decreaserdiovascular Surgery c Volume 142, Number 4 801
TABLE 1. Baseline characteristics of patients with aortic valve
replacement
Characteristic
Mild-to-moderate
PH (n ¼ 114)
Severe PH
(n ¼ 35)
P
value
Mean (SD) age (y) 71 (12) 75 (10) .04
Male (%) 61 (53.5) 18 (51.4) .8
Smoking history (%) 61 (53.5) 16 (45.7) .4
Mean (SD) BMI (kg/m2) 28.2 (5.8) 30.1 (6.8) .1
Medical history (%)
Hypertension 83 (72.8) 28 (80) .4
Diabetes mellitus 28 (24.6) 16 (45.7) .02
Prior myocardial infarction 26 (22.8) 7 (20) .7
COPD 29 (25.4) 8 (22.9) .8
Atrial fibrillation 27 (23.7) 14 (40) .06
Symptoms (%)
Angina 24 (21.1) 4 (11.4) .2
Presyncope/syncope 19 (16.7) 2 (5.7) .1
Dyspnea 83 (72.8) 30 (85.7) .1
NYHA class 3/4 21 (18.4) 16 (45.7) .001
Mean (SD) STS score 3.6 (2.8) 6.9 (3.9) <.001
Mean (SD) serum creatinine
(mg/dL)
1.1 (0.4) 1.8 (1.8) .02
Echocardiographic measurements
Mean (SD) AVA (cm2) 0.75 (0.1) 0.67 (0.2) .02
Bicuspid valve (%) 25 (21.9) 1 (2.9) .009
Average (SD) baseline left
ventricular ejection fraction
percent
53.1 (12.3) 44.1 (13.7) .001
Average (SD) baseline peak
gradient across aortic valve
(mm Hg)
67.8 (25.3) 66.9 (21.9) .9
Average (SD) baseline mean
gradient across aortic valve
(mm Hg)
38.7 (16.0) 39.3 (15.4) .8
Hemodynamic measurements
Average (SD) baseline systolic
PAP (mm Hg)
36.4 (9.4) 70.5 (14.6) <.001
Average (SD) baseline diastolic
PAP (mm Hg)
15.6 (5.5) 31.5 (7.1) <.001
Average (SD) baseline mean
PAP (mm Hg)
22.5 (6.6) 45.3 (8.3) <.001
Average (SD) baseline PCWP
(mm Hg)
14.6 (6.1) 26.8 (7.0) <.001
Average (SD) baseline cardiac
index (L/min/m2)
2.5 (0.7) 2.7 (3.1) .7
Average (SD) baseline LVEDP
(mm Hg)
16.0 (6.4) 24.9 (9.1) <.001
Average (SD) baseline
pulmonary vascular
resistance (dynes/sec/cm5)
151.6 (89.9) 399.3 (215.6)<.001
PH, Pulmonary hypertension; SD, standard deviation; BMI, body mass index;COPD,
chronic obstructive pulmonary disease; NYHA, New York Heart Association; SD,
standard deviation; STS, Society of Thoracic Surgeons score; AVA, aortic valve
area; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure;
LVEDP, left ventricular end-diastolic pressure.
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carried out to determine significant predictors of response post-AVR.
RESULTS
Baseline Characteristics
For the study period (January 2004 to April 2009), we
identified 317 patients with severe AS who underwent left
and right heart catheterization andmet all eligibility criteria.
Among these patients, 81 (25.2%) had severe PH. A total of
35 of 81 patients (43.2%) (mean PAP range, 36–74 mmHg)
underwent AVR during the study period, and 46 patients
did not. Among the patients with mild-to-moderate PH,
114 underwent AVR during the study period.
Table 1 shows the baseline characteristics of patients un-
dergoing AVR. In this population selected to receive a right
heart catheterization, the severe PH group was significantly
older than the mild-to-moderate PH group. Compared with
patients in the mild-to-moderate PH group, those in the se-
vere PH group more frequently had diabetes and atrial fi-
brillation. The clinical presentation of both groups had
similar frequencies of angina, dyspnea, and syncope-
presyncope, but more patients in the severe PH group
were in NYHA class 3 to 4. Mean serum creatinine levels
and mean calculated STS scores were higher in the severe
PH group.
Baseline echocardiographic and hemodynamic charac-
teristics of patients undergoing AVR are presented in
Table 1. In the mild-to-moderate PH group, more patients
had a bicuspid aortic valve. Average baseline AVA was
lower in the severe PH group (mean [standard deviation]:
0.67  0.2 cm2 vs. 0.75  0.1 cm2, P ¼ .02), but average
baseline peak and mean gradients across the aortic valve
were similar in both groups. Furthermore, average baseline
left ventricular ejection fraction was lower in the severe PH
group compared with the mild-to-moderate PH. The severe
PH group had higher preoperative LVEDP, PCWP, and
mean pulmonary vascular resistance. Average systolic
PAP was 36.4  9.4 mm Hg in the mild-to-moderate PH
group and 70.5  14.6 mm Hg in the severe PH group. In
all the patients in the severe PH group, systolic PAP was
 55 mm Hg. Moderate-to-severely depressed right ventri-
cle systolic function was observed in 6 patients (5.26%) in
the mild-to-moderate PH group and in 2 patients (5.71%) in
the severe PH group (P ¼ .9).
Patients with severe PH who did not undergo AVR had
similar age (76.3  11.5 years), gender distribution (male
67%), mean PAP (44.2  6.3 mm Hg), cardiac index (2.2
 0.7), and STS scores (5.7  3.7) compared with patients
with severe PH who did not undergo AVR. The reasons for
not undergoing surgery are listed in Table 2.
Operations
In addition to AVR, 51 patients (44.73%) in the mild-
to-moderate PH group and 13 patients (37.14%) in the802 The Journal of Thoracic and Cardiovascular Surgsevere PH group underwent concomitant coronary artery
bypass grafting (P ¼ .09). On the other hand, 13 patients
(11.4%) in the mild-to-moderate PH group and 8 patientsery c October 2011
TABLE 2. Reasons why patients with severe aortic stenosis and severe
pulmonary hypertension were not selected for aortic valve
replacement
Reason
Medical treatment
(n ¼ 46)
Cardiac conditions
(severe left ventricle dysfunction, cardiogenic
shock, severe mitral regurgitation, porcelain aorta)
8 (17.4%)
Malignancy
(lung cancer, lymphoma)
2 (4.3%)
Other
(severe debilitation, end-stage liver disease,
end-stage kidney disease, cerebrovascular
accident, sepsis, pulmonary embolus, major
bleeding, connective tissue disease, amyloidosis)
22 (47.9%)
Patient’s preference 6 (13.0%)
Asymptomatic 8 (17.4%)
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mitral valve replacement (P ¼ .032).Follow-up, Mortality, and Postoperative
Complications
Postoperative patient characteristics of patients undergo-
ing AVR are presented in Table 3. Mean follow-up was 548
 530 days in the mild-to-moderate PH group and 347 
347 days in the severe PH group (P ¼ .01). Seven deaths
(6.14%) in the mild-to-moderate PH group and 1 death
(2.85%) in the severe PH group were observed within the
30-day postoperative period (P ¼ .5). One-year mortalityTABLE 3. Postoperative characteristics of patients with aortic valve
replacement
Characteristic
Mild-to-moderate
PH
Severe
PH
P
value
Mean (SD) follow up available
in days
548 (530) 347 (347) .01
Total deaths encountered to end
of follow-up period (%)
23 (20.2) 5 (14.3) .4
Death in 1 y after AVR (%) 17 (14.9) 3 (8.6) .3
Mean (SD) length of hospital
stay in days
12.7 (10.7) 17.1 (12.3) .09
NYHA class 3/4 (%) 26 (22.8) 11 (31.4) .3
Postoperative complications (%)
Stroke 3 (2.6) 1 (2.9) .9
Renal insufficiency 11 (9.7) 5 (14.3) .4
Dialysis 2 (1.8) 1 (2.9) .7
Sepsis 5 (4.4) 2 (5.7) .7
Multiorgan failure 2 (1.8) 1 (2.9) .7
Permanent pacemaker
placement
6 (5.3) 1 (2.9) .6
Atrial fibrillation 26 (22.8) 9 (25.7) .7
Tracheostomy 9 (7.9) 4 (11.4) .5
SD, Standard deviation; AVR, aortic valve replacement; PH, pulmonary hypertension;
NYHA, New York Heart Association.
The Journal of Thoracic and Cawas 14.9% (17 deaths) in the mild-to-moderate PH group
and 8.6% (3 deaths) in the severe PH groups (P¼ .3). Over-
all mortality was 23 (20.2%) in the mild-to-moderate PH
group and 5 (14.2%) in the severe PH group (P ¼ .4) at
the end of follow-up period. In the mild-to-moderate PH
group, cardiopulmonary events (17 patients), alveolar
hemorrhage (1 patient), lung cancer (1 patient), sepsis
(1 patient), ischemic bowel (1 patient), acute lymphocytic
leukemia (1 patient), and multiorgan failure (1 patient)
were causes of death. In the severe PH group, cardiopulmo-
nary events (3 patients), sepsis (1 patient), and ischemic
bowel (1 patient) were causes of death. Length of hospital
stay was not significantly different in the severe and non-
severe PH groups. In both groups, similar percentages of pa-
tients were in NYHA class 3 or 4 after surgery. Postopera-
tive complications were also similar in both groups. Three
patients in the mild-to-moderate PH group and 2 patients
in the severe PH group had pneumonia in the postoperative
period. In the mild-to-moderate PH group, 20 patients
required intubation more than 24 hours (>72 hours in 14 pa-
tients), whereas 8 patients required intubation more than 24
hours (>72 hours in 5 patients) in the severe PH group.
There was no significant difference in median-term mortal-
ity between the mild-to-moderate and severe PH groups, as
seen in the Kaplan–Meier unadjusted analysis (P ¼ .8)
(Figure 1).
In patients with severe PH who did not undergo AVR,
5 deaths (10.86%) were observed during the 30 days after
index heart catheterization. Among these patients, 1-year
mortality and overall mortality at the end of study period
were 39.13% (18 deaths) and 50% (23 deaths), respec-
tively. In this patient group, 10 patients (21.7%) under-
went balloon aortic valvuloplasty during the study
period. In the Kaplan–Meier unadjusted analysis, patients
with severe AS who underwent AVR had significantly
better survival compared with patients with severe AS
who did not undergo surgery (P ¼ .002) (Figure 2). In
the mild-to-moderate PH group, overall mortality was
higher in patients not undergoing AVR (36 deaths among
112 patients) compared with patients undergoing AVR
(P ¼ .03).
Predictors of Mortality in Patients With Aortic Valve
Replacement
In patients undergoing AVR, baseline mean PAP was not
an independent predictor of mortality in adjusted analysis
(hazard ratio [HR], 1.008; 95% confidence interval [CI],
0.91–1.11; P ¼ .86). However, early postoperative reduc-
tion in mean PAP was an independent predictor (HR,
0.93; 95% CI, 1.2–12.5; P ¼ .048). In addition, COPD
was found to be an independent predictor of mortality
(HR, 3.5; 95% CI, 1.29–9.59; P ¼ .014). Age, gender,
body mass index, valve morphology, NHYA class, hyper-
tension, diabetes, atrial fibrillation, smoking history,rdiovascular Surgery c Volume 142, Number 4 803
FIGURE 1. Kaplan–Meier curves comparing survival in the mild-to-moderate and severe PH groups with AVR (P value using log rank statistic: .8).
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transvalvular aortic gradient, mean PCWP, pulmonary vas-
cular resistance, STS score, and concomitant mitral valve
replacement did not predict mortality in patients with severeFIGURE 2. Kaplan–Meier curves comparing survival in the AVR and non-AV
.002).
804 The Journal of Thoracic and Cardiovascular SurgASwho underwent AVR. Only 5 deaths occurred in patients
with baseline mean PAP greater than 35 mm Hg. Further-
more, postoperative mean PAP in 4 of these 5 deaths was
still 35 mm Hg or greater (Figure 3).R groups among patients with severe PH (P value using log rank statistic:
ery c October 2011
FIGURE 3. Two-dimensional scatter plot with preoperative mean PAP on the x axis and postoperative mean PAP on the y axis stratified by death.
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Patients With Aortic Valve Replacement
Systolic PAP reduction was significant in both severe and
mild-moderate PH groups (Table 4), whereas diastolic and
mean PAP reductions were significant only in the severe
PH group. In the severe PH group, preoperative and postop-
erative mean PAPs were 45.3  8.3 mm Hg and 29.0  6.8
mm Hg, respectively (P<.001); however, in the mild-to-
moderate PH group these were 22.5  6.6 mm Hg and
21.7  6.1 mm Hg, respectively (P ¼ .1). In patients with
severe PH who did not require concomitant MVR, there
was a significant reduction in mean PAP after surgery. InTABLE 4. Comparison of preoperative and postoperative hemo-
dynamic changes in patients with aortic valve replacement
Characteristic Preoperative Postoperative
P
value
Net
change
Systolic PAP (mm Hg)
Mild-to-moderate PH 36.4 (9.4) 34.1 (10.3) .008 2.7 (10.2)
Severe PH 70.5 (14.6) 47.9 (12.0) <.00122.5 (14.4)
P value <.001 <.001
Diastolic PAP (mm Hg)
Mild-to-moderate PH 15.6 (5.5) 15.6 (4.9) .9 0.01 (6.5)
Severe PH 31.5 (7.1) 19.7 (5.4) <.00111.8 (7.6)
P value <.001 <.001
Mean PAP (mm Hg)
Mild-to-moderate PH 22.5 (6.6) 21.7 (6.1) .1 0.9 (7.0)
Severe PH 45.3 (8.3) 29.0 (6.8) <.00116.2 (9.0)
P value <.001 <.001
PAP, Pulmonary artery pressure; PH, pulmonary hypertension. A negative net change
implies reduction as compared with the preoperative value. All values expressed as
mean (SD).
The Journal of Thoracic and Cathese patients, preoperative and postoperative mean PAPs
were 44.6  8.2 mm Hg and 27.2  4.4 mm Hg, respec-
tively (P< .001). In a detailed analysis, we determined
that, in both the mild-to-moderate PH and severe PH
groups, patients who survived showed significant reduc-
tions in their mean PAP after AVR (Table 5). However,
this reduction was not significant among patients who did
not survive.
The study population was divided into 2 groups (re-
sponders and nonresponders), and a multivariate prediction
modeling based on semiparametric Cox proportional hazard
modeling was performed to determine preoperative predic-
tors of reduction in mean PAP (Figure 4). High preoperative
PCWP (odds ratio [OR], 1.26; 95% CI, 1.13–1.41;
P<.0001) was a significant preoperative predictor of reduc-
tion of mean PAP. AVA (OR, 0.01; 95% CI, 0.0001–1.03;
P ¼ .052), atrial fibrillation (OR, 0.27; 95% CI, 0.06–
1.08; P ¼ .066), and previous myocardial infarction
(OR, 0.22; 95% CI, 0.04–1.16; P ¼ .075) tended to be pre-
dictors of reduced mean PAP, but they remained statistically
insignificant.DISCUSSION
In our study group, mortality after AVR was similar
whether patients had mild-to-moderate or severe PH. Post-
operative morbidities, postoperative NYHA class III to IV,
and length of hospital stay also were similar in both mild-
to-moderate and severe PH groups. In a multivariate analy-
sis, COPD and postoperative reduction in mean PAP were
independent predictors of mortality but not the baseline
PAP. Preoperative high mean PCWP was a significantrdiovascular Surgery c Volume 142, Number 4 805
TABLE 5. Mean pulmonary artery pressure changes postoperatively compared with baseline preoperative pulmonary artery pressures stratified
by mortality at the end of follow-up
Characteristic Dead (n ¼ 28) Survivors (n ¼ 121)
Mild-to-moderate PH Preoperative mean PAP 23.6 (6.3) Preoperative mean PAP 22.5 (6.8)
Postoperative mean PAP 24.6 (7.2) Postoperative mean PAP 20.9 (5.5)
Net change: 1.0 (7.7) Net change 1.5 (6.7)
P value .5 P value .04
Severe PH Preoperative mean PAP 51.2 (15.5) Preoperative mean PAP 44.3 (6.4)
Postoperative mean PAP 36.1 (8.7) Postoperative mean PAP 27.9 (5.8)
Net change 15.1 (36.3) Net change 16.4 (7.4)
P value 0.1 P value <.001
PH, Pulmonary hypertension; PAP, pulmonary artery pressure. A negative net change implies reduction compared with the preoperative value. All values expressed as mean (SD).
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PH had higher preoperative LVEDP and pulmonary vascu-
lar resistance compared with the mild-to-moderate PH
group, and they had a rapid and prominent reduction in
PAP after AVR.
The significance of high PAP in patients with severe AS
remains controversial. A correlation has been demonstrated
between increased PAP and left ventricle diastolic dysfunc-
tion in patients with severe AS.1-3,5,13,14 It is possible that
severe PH is reactive in these patients and does not
represent pulmonary vascular disease.3,14 Some studies
have demonstrated rapid reduction in systolic, diastolic,FIGURE 4. Multivariate logistic regression analysis for preoperative predicto
entire study population was divided into 2 groups: responders (patients with 1
Hg reduction after AVR).
806 The Journal of Thoracic and Cardiovascular Surgand mean PAP after AVR, resulting in improvement in
clinical outcomes.4,13 Further, it has been suggested that
there is better survival with AVR compared with medical
management in these patients.14,16 Mortality after AVR
varies in different studies depending on concomitant
morbidities, exclusion criteria, and definition for severe
PH. For instance, a recent report showed 34% mortality
at 5-year follow-up,16 whereas Malouf and coworkers14 re-
ported 32%mortality at a median of 460 days follow-up. In
the latter study, only 26% of the study population (12/47
patients) underwent formal right heart catheterization.14
In another echocardiography-based study, long-termrs of reduction in mean PAP. According to the reduction of mean PAP, the
0 mm Hg reduction after AVR) and nonresponders (patients with<10 mm
ery c October 2011
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AVR were similar, irrespective of their PAP.16 These 2 stud-
ies compared only medical treatment with surgical AVR in
patients with severe AS and severe PH. In addition to this
comparison, our study compared the mild-moderate PH
group with the severe PH group in patients with severe
AS who underwent surgical AVR. Le Tourneau and
colleagues21 assessed the impact of cardiovascular risk
factors on early and late outcomes in severe AS after
AVR. In their study, systolic PAP was a predictor of mortal-
ity in univariate analysis. But, in multivariate analysis, only
age, diabetes, male gender, and NHYA class remained as
independent predictors of mortality. Two small cardiac
catheterization database studies evaluating post-AVR mor-
tality differences in patients with severe AS showed similar
mortality in both the mild and severe PH groups.1,4 Even the
STS risk score included PAP in the calculation to January
2009, but the most recent calculator does not include PAP
for risk assessment.11
Our study is the first large hemodynamic database study
to analyze the impact of PH in patients with severe AS.
Right heart catheterization enabled direct measurement of
PAP and PCWP. Unlike previous cardiac catheterization-
based studies that reported only operative mortality,1,4 we
report long-term mortality results. We showed that patients
with AS and severe preoperative PH hadmortality similar to
those with mild-to-moderate preoperative PH after AVR.
Furthermore, we observed that baseline PH does not affect
survival in these patients after AVR. The current study also
reported PAP after surgery from invasive pressure measure-
ments. Multivariable analysis, made possible by the larger
sample size, suggested that severe PH is reactive to in-
creased LVEDP in these patients and rapidly declines after
surgery. Reduction in mean PAPwas one of the independent
predictors of survival after AVR and was seen in patients
with severe PH and patients with mild-to-moderate PH. In
the severe PH group, 4 of 5 patients who died after AVR
(1 died of intestinal ischemia and bleeding, and 3 died of
cardiopulmonary failure) still had high postoperative
mean PAP. Furthermore, patients with a higher preoperative
PCWP had a tendency for greater postoperative reduction in
mean PAP. The last reading from the Swan-Ganz catheter
was used as the final PAP measurement, which in turn
was used to calculate the decrease in mean PAP. Because
left ventricle remodeling requires time after the surgery,
measuring the change in PAP in the immediate postopera-
tive may underestimate response. Despite this limitation,
an early decrease in PAP leads to better long-term
outcomes.
Severe PH should not be a contraindication for AVR in
patients with severe AS, especially if there is increased fill-
ing pressures as measured by higher PCWP. Patients with
severe AS who have severe PH can undergo AVR with
low mortality and derive substantial benefit from theThe Journal of Thoracic and Casurgery. Patients who show a higher postoperative reduction
in their mean PAP have notably better prognosis. The
magnitude of reduction in mean PAP can provide an early
indication for success. It seems that AVR provides substan-
tial benefit to these patients.
Limitations
Our study is a retrospective observational study; thus, the
physician bias in patient selection is unavoidable. Similarly,
because of the relatively small sample size, we might not
have accounted for all confounding variables. We are un-
able to answer completely the question of how physicians
selected these patients to undergo AVR compared with
those with PH who did not undergo AVR.
At the Cleveland Clinic, most patients with severe AS un-
dergo only left heart catheterization before surgery. Right
heart catheterization is reserved for patients with questions
regarding cardiac hemodynamics, including PAP, cardiac
output, or AVA. This group of patients is therefore prese-
lected with hemodynamic question. We did review the
mortality of all patients undergoing only left heart catheter-
ization in the study period to understand the selection
process. Among these patients, postoperative 30-day and
1-year mortality were 1.8% and 8.5%, respectively. Sur-
vival of patients who had only left heart catheterization
was significantly better than survival of patients who under-
went both left and right heart catheterization (P¼ .004). Pa-
tients undergoing right heart catheterization were high-risk
patients for AVR as evidenced by worse survival of the
study group compared with all patients undergoing AVR
in the same period. The high mortality at 1 year even in
patients with mild-to-moderate PH also signifies that these
patients have many comorbidities.
CONCLUSIONS
The prognosis of patients with severe AS and PHwho did
not undergo AVR is poor. Potential benefits of AVR may
outweigh the risk of surgery, with survival comparable to
that of other high-risk patients with nonsevere PH if other
comorbidities do not prohibit operation. Higher preopera-
tive PCWP predicts a more marked reduction in mean
PAP, which ultimately predicts improved survival. There-
fore, patients with severe PH should seriously be considered
for AVR especially if the PCWP is high. It seems that PH is
reactive in a majority of these patients with rapid decline
after AVR.
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